PP2A-Mediated Anticancer Therapy

<table class="table-group" id="tab3"><tr><td><table class="table"><tr><td class="thead-hr" colspan="4"><hr/></td></tr><tr class="thead"><td align="left">Inhibitory protein</td><td align="center">Interaction with PP2A</td><td align="center">Drugs against inhibitory</td><td align="center">References</td></tr><tr><td class="thead-hr" colspan="4"><hr/></td></tr><tr><td align="left">CIP2A</td><td align="center">Prevent PP2A-dependent dephosphorylating of c-Myc</td><td align="center">Bortezomib; Erlotinib</td><td align="center">[<a href="/journals/grp/2013/675429/#B32">32</a>–<a href="/journals/grp/2013/675429/#B35">35</a>]</td></tr><tr><td align="left">PHAPI/pp32/<svg height="20.275" id="M56" style="vertical-align:-3.27605pt" version="1.1" viewbox="0 0 33.8125 20.275" width="33.8125" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink">
<g transform="matrix(.017,-0,0,-.017,.062,16.137)"><path d="M303 0h-265v28q62 5 76 19.5t14 77.5v400q0 63 -14 77.5t-76 19.5v28h265v-28q-62 -5 -76 -19.5t-14 -77.5v-400q0 -64 14 -78t76 -19v-28z" id="x49"></path></g>
<g transform="matrix(.012,-0,0,-.012,5.862,7.975)"><path d="M46 650h247q112 0 169 -41q64 -49 64 -141q0 -91 -56.5 -143t-138.5 -62q-23 -3 -45 -1l-74 19v-157q0 -63 15.5 -77t83.5 -19v-28h-271v28q60 5 74 20t14 77v400q0 65 -12.5 79t-69.5 18v28zM212 559v-245q31 -12 73 -12q59 0 102 38t43 124q0 77 -42.5 115.5
t-108.5 38.5q-44 0 -56 -12q-11 -8 -11 -47z" id="x50"></path></g><g transform="matrix(.012,-0,0,-.012,12.502,7.975)"><path d="M46 650h247q112 0 169 -41q64 -49 64 -141q0 -91 -56.5 -143t-138.5 -62q-23 -3 -45 -1l-74 19v-157q0 -63 15.5 -77t83.5 -19v-28h-271v28q60 5 74 20t14 77v400q0 65 -12.5 79t-69.5 18v28zM212 559v-245q31 -12 73 -12q59 0 102 38t43 124q0 77 -42.5 115.5
t-108.5 38.5q-44 0 -56 -12q-11 -8 -11 -47z" id="x50"></path></g>
<g transform="matrix(.012,-0,0,-.012,19.2,7.975)"><path d="M384 0h-275v27q67 5 81.5 18.5t14.5 68.5v385q0 38 -7.5 47.5t-40.5 10.5l-48 2v24q85 15 178 52v-521q0 -55 14.5 -68.5t82.5 -18.5v-27z" id="x31"></path></g>
<g transform="matrix(.012,-0,0,-.012,24.912,7.975)"><path d="M673 0h-245v28q47 6 58 16t1 39l-55 154h-213q-31 -87 -36 -129q-16 -47 -5 -61t68 -19v-28h-226v28q50 7 68.5 23.5t43.5 80.5l214 524l24 9l193 -536q23 -63 41.5 -79.5t68.5 -21.5v-28zM418 280l-81 255h-2q-74 -197 -101 -255h184z" id="x41"></path></g>
<g transform="matrix(.012,-0,0,-.012,5.862,20.213)"><path d="M412 140l28 -9q0 -2 -35 -131h-373v23q112 112 161 170q59 70 92 127t33 115q0 63 -31 98t-86 35q-75 0 -137 -93l-22 20l57 81q55 59 135 59q69 0 118.5 -46.5t49.5 -122.5q0 -62 -29.5 -114t-102.5 -130l-141 -149h186q42 0 58.5 10.5t38.5 56.5z" id="x32"></path></g>
</svg></td><td align="center">Direct binding</td><td align="center">Jacalin</td><td align="center">[<a href="/journals/grp/2013/675429/#B39">39</a>, <a href="/journals/grp/2013/675429/#B40">40</a>]</td></tr><tr><td align="left">SET/<svg height="20.275" id="M57" style="vertical-align:-3.27605pt" version="1.1" viewbox="0 0 39.487499 20.275" width="39.487499" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink">
<g transform="matrix(.017,-0,0,-.017,.062,16.137)"><path d="M303 0h-265v28q62 5 76 19.5t14 77.5v400q0 63 -14 77.5t-76 19.5v28h265v-28q-62 -5 -76 -19.5t-14 -77.5v-400q0 -64 14 -78t76 -19v-28z" id="x49"></path></g>
<g transform="matrix(.012,-0,0,-.012,5.862,7.975)"><path d="M46 650h247q112 0 169 -41q64 -49 64 -141q0 -91 -56.5 -143t-138.5 -62q-23 -3 -45 -1l-74 19v-157q0 -63 15.5 -77t83.5 -19v-28h-271v28q60 5 74 20t14 77v400q0 65 -12.5 79t-69.5 18v28zM212 559v-245q31 -12 73 -12q59 0 102 38t43 124q0 77 -42.5 115.5
t-108.5 38.5q-44 0 -56 -12q-11 -8 -11 -47z" id="x50"></path></g><g transform="matrix(.012,-0,0,-.012,12.502,7.975)"><path d="M46 650h247q112 0 169 -41q64 -49 64 -141q0 -91 -56.5 -143t-138.5 -62q-23 -3 -45 -1l-74 19v-157q0 -63 15.5 -77t83.5 -19v-28h-271v28q60 5 74 20t14 77v400q0 65 -12.5 79t-69.5 18v28zM212 559v-245q31 -12 73 -12q59 0 102 38t43 124q0 77 -42.5 115.5
t-108.5 38.5q-44 0 -56 -12q-11 -8 -11 -47z" id="x50"></path></g>
<g transform="matrix(.012,-0,0,-.012,19.2,7.975)"><path d="M412 140l28 -9q0 -2 -35 -131h-373v23q112 112 161 170q59 70 92 127t33 115q0 63 -31 98t-86 35q-75 0 -137 -93l-22 20l57 81q55 59 135 59q69 0 118.5 -46.5t49.5 -122.5q0 -62 -29.5 -114t-102.5 -130l-141 -149h186q42 0 58.5 10.5t38.5 56.5z" id="x32"></path></g>
<g transform="matrix(.012,-0,0,-.012,24.912,7.975)"><path d="M673 0h-245v28q47 6 58 16t1 39l-55 154h-213q-31 -87 -36 -129q-16 -47 -5 -61t68 -19v-28h-226v28q50 7 68.5 23.5t43.5 80.5l214 524l24 9l193 -536q23 -63 41.5 -79.5t68.5 -21.5v-28zM418 280l-81 255h-2q-74 -197 -101 -255h184z" id="x41"></path></g>
<g transform="matrix(.012,-0,0,-.012,5.862,20.213)"><path d="M412 140l28 -9q0 -2 -35 -131h-373v23q112 112 161 170q59 70 92 127t33 115q0 63 -31 98t-86 35q-75 0 -137 -93l-22 20l57 81q55 59 135 59q69 0 118.5 -46.5t49.5 -122.5q0 -62 -29.5 -114t-102.5 -130l-141 -149h186q42 0 58.5 10.5t38.5 56.5z" id="x32"></path></g>
</svg></td><td align="center">Direct binding</td><td align="center">COG112; Apolipoprotein E-mimetis peptides</td><td align="center">[<a href="/journals/grp/2013/675429/#B39">39</a>, <a href="/journals/grp/2013/675429/#B43">43</a>, <a href="/journals/grp/2013/675429/#B44">44</a>]</td></tr><tr><td align="left">SETBP1</td><td align="center">Form a SETBP1-SET-PP2A complex</td><td align="center"> </td><td align="center">[<a href="/journals/grp/2013/675429/#B45">45</a>]</td></tr><tr class="table-tr"><td colspan="4"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

Inhibitory protein of PP2A and possible related anticancer drugs.

Gastroenterology Research and Practice

tab3

Table 3

Table 3: PP2A-Mediated Anticancer Therapy 